4822735 T cell growth factor and method of making same

PATENT Hepatitis B virus and a vaccine containing fusion protein are also described.

this

MODULATION OF AIDS VIRUSRELATED EVENTS BY DOUBLESTRANDED RNAS assigned

425

4822470 METHOD OF AND APPARATUS FOR CELL PORATION AND CELL FUSION USING RADIOFREQUENCY ELECTRICAL PULSES

4820696

William A Carter Inc

ABSTRACTS

to HEM Research

The use of mismatched dsRNA, e.g. Amphgen for the manufacture of compositions for use in the Selective activation of a latent natural defense system within human cells, both cells already infected with AIDS virus as well as cells at risk to infection. Specific treatments for various clinical phases of the biological continuum of AIDS virus-related events ranging from subtle, early immunological lesions to advanced disease are described. Prophylaxis or prevention of AIDS virus related events, such as by introduction of mismatched double-stranded RNA into various blood products of biological fluids to be used in man (e.g., blood transfusion) or around man (e.g., dialysis programs) are also described.

Donald C Chang assigned to Baylor College of Medicine Disclosed are an apparatus and a method for the poration and fusion of cells using radiofrequency electrical pulses. The electrodes of the apparatus can be hand held or part of integrated equipment with special containers for cells. The electrodes, which are positioned equal distance from each other, are attached to a power function generator. The power function generator can apply a continnous AC electrical field and/or a pulsed radiofrequency electrical field across the electrodes. The alternating electrical field induces cell dielectrophoresis. The pulsed radiofrequency electrical field porates or fuses the cells. The method can be used to fuse or porate a variety of cells including erythrocyte ghosts, liposomes, vesicles, isolated cells and cultured cells. During the poration or fusions a variety of chemical agents including antibodies, proteins, drugs, molecular probes, hormones, growth factors, DNA, RNA, enzymes, organic chemicals and inorganic chemicals can be introduced into these cells. The method can also be used to produce new species and to make hybridoma cells which produce monoclonal antibodies.

4820812 OLIGONUCLEOTIDE DERIVATIVES AND PRODUCTION THEREOF Kenichi Miyoshi, Toru Fuwa, Hiroshima, Japan assigned to Wakunaga Seiyaku Kabushiki Kaisha An oligonucleotide derivative having an amino group protected with an eliminatable group bonded through a phosphate group and a spacer with an appropriate length to the Y-end of an oligonucleotide protected suitably at the 3’hydroxyl group and the base moiety of the nucleotide, and an immobilized oligonucleotide derivative having a Sepharose carrier bonded to the amino group in place of said protective group are disclosed. Methods for production of these derivatives are also disclosed.

4822735 T CELL GROWTH FACTOR AND METHOD OF MAKING SAME David W Anderson assigned to Eleanor Roosevelt Institute for Cancer Research Inc A mutant T-cell line of HSB-2-ERICR which produces a T cell Growth Factor is disclosed. The Mutant cells are sensitive to HAT Medium.